FDA Approved: ONPATTRO — Original Application (Alnylam Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved ONPATTRO (patisiran) as the original application for hereditary transthyretin-mediated amyloidosis with polyneuropathy, developed by Alnylam Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• Onpattro (patisiran)

Snippet

ORIG AP for ONPATTRO (PATISIRAN)